FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number: 3235-028									
l	Estimated average burden									
	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Roberts Christopher D. (Last) (First) (Middle) C/O BLACK DIAMOND THERAPEUTICS, INC.							Issuer Name and Ticker or Trading Symbol Black Diamond Therapeutics, Inc. [BDTX] Jate of Earliest Transaction (Month/Day/Year) 12/03/2020									of Reporting Person(s) to Issuer licable) for 10% Owner or (give title Other (specific) below) Chief Scientific Officer			vner
(Street) CAMBR (City)	IN STREET IDGE M (S	_ 4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
		Tab	le I - N	Non-Deriv	vative	e Sec	urit	ies A	cquire	ed, D	isposed o	of, or B	enefici	ially	Owned	i			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye						Execution [3. Transaction Code (Instr. 8)		4. Securities Disposed Of		nd 5) Securi Benefi Owned		es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price			rted action(s) . 3 and 4)			(Instr. 4)
Common Stock 12/03/202						20			М		2,500	Α	\$10.).86		2,500		D	
Common	Common Stock 12/03/202					20		S ⁽¹⁾		2,500	D	\$32.42	221(2)		0		D		
		Т	able I								sposed of				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed tion Date, n/Day/Year)	4. Transa Code (8)				6. Date Exer Expiration D (Month/Day/		ate	7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		De Se (In	. Price of perivative security nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amour or Number of Shares	er					
Stock Option (Right to Buy)	\$10.86	12/03/2020			M			2,500	(3	3)	09/08/2029	Commo: Stock	n 2,500	0	\$0.00	179,309)	D	

Explanation of Responses:

- $1. \ Shares \ sold \ pursuant \ to \ a \ pre-established \ 10b5-1 \ trading \ plan \ effective \ as \ of \ June \ 2, \ 2020.$
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$31.985 to \$32.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 3. 25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter.

Remarks:

/s/ Brent Hatzis-Schoch, as 12/04/2020 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.